Asthma therapeutics: Past, present, and future

Area of Science:

• Pulmonology and immunology
• Pharmacology and drug discovery

Background:

• Asthma, a chronic airway inflammatory disease affecting over 300 million globally, has seen treatment evolve significantly since its initial recognition.
• Early 20th-century advancements introduced immunotherapy and inhaled corticosteroids, while the 21st century accelerated the development of novel pharmacotherapies.

Purpose of the Study:

• To review the historical standard-of-care asthma treatment strategies.
• To outline current asthma management recommendations.
• To explore emerging novel therapies and future directions in personalized asthma medicine.

Main Methods:

• Review of historical and current literature on asthma treatment paradigms.
• Analysis of the impact of novel biologic therapies on asthma control.
• Discussion of emerging therapeutic targets and personalized medicine approaches.

Main Results:

• Biologic therapies, including monoclonal antibodies targeting IgE, TSLP, IL-4, IL-5, and IL-13, have revolutionized severe asthma care.
• These targeted treatments reduce exacerbations, lower oral corticosteroid doses, improve lung function, and enhance quality of life.
• Despite advancements, current biologic therapies represent an early stage in personalized asthma management.

Conclusions:

• Asthma treatment has shifted from broad anti-inflammatory and bronchodilatory therapies to precisely targeted biologic agents.
• Understanding asthma phenotypes and endotypes facilitates precision medicine, with monoclonal antibodies offering significant benefits for severe cases.
• Future research promises further personalization of asthma treatment, improving outcomes and quality of life for a wider patient population.